Dr. Lonial Discusses Recent Updates in Multiple Myeloma

Sagar Lonial, MD
Published Online: Thursday, Mar 09, 2017



Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Recently, highly active induction regimens that combine proteasome inhibitors and IMiDS with transplant and risk adapted maintenance have been shown to put most patients into remission for 3 to 5 years. This contrasts with the past 15 years of treatment that, according to Lonial, lacked effective drugs in the induction therapy setting.

Immune-based agents such elotuzumab (Empliciti) and daratumumab (Darzalex) are also in the mix, as well as other small molecules in development, says Lonial.
 


Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Recently, highly active induction regimens that combine proteasome inhibitors and IMiDS with transplant and risk adapted maintenance have been shown to put most patients into remission for 3 to 5 years. This contrasts with the past 15 years of treatment that, according to Lonial, lacked effective drugs in the induction therapy setting.

Immune-based agents such elotuzumab (Empliciti) and daratumumab (Darzalex) are also in the mix, as well as other small molecules in development, says Lonial.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
$emailPop$
x